Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
| Revenue (Most Recent Fiscal Year) | $1.24B |
| Net Income (Most Recent Fiscal Year) | $-535.98M |
| PE Ratio (Current Year Earnings Estimate) | 59.73 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 9.68 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 13.87 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -41.83% |
| Net Margin (Trailing 12 Months) | -43.11% |
| Return on Equity (Trailing 12 Months) | -18.97% |
| Return on Assets (Trailing 12 Months) | -4.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.95 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.45 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.32 |
| Inventory Turnover (Trailing 12 Months) | 0.60 |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.19 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.47 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.80 |
| Diluted Earnings per Share (Trailing 12 Months) | $-6.12 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 94.51M |
| Free Float | 86.95M |
| Market Capitalization | $12.04B |
| Average Volume (Last 20 Days) | 0.69M |
| Beta (Past 60 Months) | 0.94 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.68% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |